1 To assess neurological, cardiovascular, metabolic and other side-effects of mefloquine given in conventional prophylactic dose to healthy volunteers, a double-blind, randomized, placebo-controlled trial was conducted. In addition, the identity of the active drug was concealed until the end of the trial. 2 A total of 106 healthy adults were recruited, of whom 95 (mean age 24 years; 45% males) completed the full study protocol. 3 Subjects had a baseline assessment, received placebo as first dose, were randomized to mefloquine 250 mg or placebo weekly for 4 weeks starting a week later, and were reassessed after the 2nd and 4th active/placebo doses. Subjects kept a daily symptom diary from 2 weeks before until 2 weeks after the dosing period. 4 Plasma mefloquine assay suggested compliance in all 46 subjects allocated active treatment (week 5 mean±s.d.; 2.35±0.94 mmol l−1). Mefloquine did not alter calcium homoeostasis but produced a mean 0.5 mmol l−1 fall in serum glucose over the study period (P<0.001) and relative hyperinsulinaemia. Symbol digit modalities, and digit forwards and backwards test scores, were similar in active and placebo groups across the three assessments, as were lying/standing blood pressure and high-tone hearing loss. Electrocardiographic QT c interval prolongation and diarrhoea were mild but transient side-effects of mefloquine (P<0.01). Neurological symptoms were comparable in the two groups throughout the study. There was no evidence of drug toxicity in 11 subjects who withdrew. 5 Mefloquine prophylaxis does not appear to produce low-grade but debilitating neurological symptoms or to alter the results of sensitive tests of cerebral function. However, there may be situations in which mefloquine might contribute to hypoglycaemia and cardiac dysrhythmias.
Introduction
are more common [ 9] , with an estimated frequency of 1 in 10,000 to 14,000 prophylactic courses [ 10, 11] .
Review of 59 such reactions has revealed that a large Mefloquine can be used as prophylaxis or treatment for malaria and covers most multi-drug resistant strains of proportion of patients had a past history of neurological or psychiatric diseases such as epilepsy and manicPlasmodium falciparum. Although large-scale studies have affirmed its relative safety and efficacy as a depressive illness [ 12] . Milder and more common neurological effects includprophylactic agent [1] [2] [3] , serious side-effects including isolated cutaneous [4] [5] [6] and marrow toxicity [ 7, 8 ] ing dizziness, vertigo, paraesthesiae, depression, fatigue, insomnia, and poor concentration and memory can have been reported. Severe neuropsychiatric reactions occur soon after ingestion of a single mefloquine dose cases, was given under supervision. Subjects received four mefloquine (LariumA, Hoffman La Roche, Basel, and persist for weeks afterwards [1, [13] [14] [15] [16] [17] . However, physician warnings of neuropsychiatric reactions, and Switzerland) 250 mg or identical placebo tablets to be taken weekly, starting a week after the initial placebo. the stresses and stimulation of travel, might produce such symptoms in susceptible individuals. A review of Venous blood was drawn for measurement of plasma mefloquine and its carboxy metabolite, serum glucose, 109 trials involving healthy subjects has revealed an adverse event frequency on placebo of 19% in single insulin, ionised calcium, phosphate, magnesium and albumin concentrations. The symbol digit modalities and 28% in multiple dose studies [18] . Headache, drowsiness, poor concentration and aesthenia are test (SDMT ) [19] and digit span forwards and backwards tests [20 ] were administered. An electrocardioreported commonly in young volunteers.
To investigate whether mild but debilitating neurologgram (ECG) was taken, blood pressure was taken supine and after two minutes' standing using an automated ical symptoms occur during a conventional prophylactic mefloquine regimen and, if so, whether metabolic system (Dynamap 1846 SX, Critikon Inc., Florida, USA), and hearing loss at 6 kHz was measured in 5 dB disturbances might contribute, we conducted a doubleblind, randomized placebo-controlled study in healthy steps using a pre-calibrated audiometer (MA40, Maico Hearing Instruments, Minneapolis, USA). volunteers who were unaware of the identity of the drug under evaluation until the end of the trial.
Subjects were asked to reattend for assessment 1 day after the third and fifth (last) tablets had been taken, at a time when plasma mefloquine concentrations would Methods be expected to be close to maximal post-dose. At these visits, diaries were reinspected and compliance checked Subjects by questioning and tablet count. Blood sampling and Subjects were healthy adult staff and students at teaching all other tests were repeated. Each subject was asked to hospitals in Perth, Western Australia. All completed a maintain the diary until 2 weeks after the last assessment standard medical questionnaire. Those with a past when it was collected. Assay of mefloquine and metabhistory of psychiatric conditions, or neurological, carolite was by high performance liquid chromatography diac, hepatic or renal disease were excluded, as were [21] . Serum glucose, albumin, phosphate and magpregnant or breast-feeding females and those with a nesium concentrations were analysed using Chem-1 known allergy to, or taking medication known to methods (Bayer Diagnostics, Tarrytown, NY). Serum interact with, quinoline drugs. None of the subjects had ionised calcium was determined using an ICA 2 taken mefloquine in the 3 months before study.
analyser (Radiometer, Copenhagen) and corrected to pH 7.40. Serum insulin was measured immunoenzymometrically (Tosoh, Tokyo, Japan). Methods
The study protocol was approved by the University of Data analysis Western Australia Human Rights Committee. Witnessed informed consent was obtained after full verbal and
To detect at least a 10% difference between the two written explanations of procedures, including advice groups for both SDMT [19 ] and digit span forwards that the identity of the active formulation would be test [20 ] using a 0.05 significance level at 80% power, concealed until the end of the study unless an adverse a minimum sample size of 47 in each group was event occurred. Tablets were prepared in individually required. For diary data, a positive symptom was taken numbered but otherwise unlabelled containers.
as a rating ≥1 for at least 1 day during a given week. Allocation of active or placebo formulation was by a Major symptoms were those rated ≥5 on any one day random number code generated by independent of the week. To assess the effect of mefloquine on Fremantle Hospital Pharmacy staff who kept the code symptoms, the proportions of subjects in whom a strictly confidential until after the last volunteer had symptom rating worsened during the first week after completed the protocol. Subjects were informed of active drug or unsupervised placebo were calculated procedures to be followed in the event of an adverse using the rating from the week following the initial reaction and an independent trial monitor was available supervised and universal placebo as baseline. The in case the randomisation code needed to be broken.
relative risk was taken as the ratio of the proportion Pregnancy tests were offered to all females who were worsening after mefloquine to that after unsupervised advised to ensure adequate contraception during, and placebo. This analysis was repeated for the week after for 3 months after, the dosing period. A diary containing the last dose, again using the rating after supervised a list of commonly reported side-effects [2, 3] (see placebo as baseline. For psychometric tests, retest gain below), together with spaces for other symptoms if (the percentage improvement or deterioration in scores required, was issued. Subjects were asked to rate each relative to baseline) at the second and third assessments standard and self-entered symptom daily at the same was calculated by the formula: time on a scale of 0 (absent) to 9 (severe).
Subjects reattended after 1 week of symptom recording to have the diary checked for completeness and to score at follow-up-score at initial assessment score at initial assessment ×100 undergo standard tests. The first tablet, placebo in all Serum insulin concentrations were log-transformed A similar pattern was seen for the listed diary symptoms lethargy, cough and the other less frequently before analysis. Statistical analysis was by parametric methods using SPSS for Windows (SPSS Inc., Chicago, positive (<10%) non-gastrointestinal complaints skin rash, itch, dizziness, hearing loss, tinnitus, memory loss, USA). Two-sample comparisons were by Student's t-test and multiple comparisons by analysis of variance.
visual disturbance, insomnia and vivid dreams. In the first week after mefloquine administration, mild abdomiPearson's correlation co-efficient was used to assess associations between variables.
nal pain and nausea increased but this trend did not reach statistical significance (see Table 1 ). However, diarrhoea worsened significantly after mefloquine (see Table 1 ; P<0.01), an effect which was transient and not associated with an increase in its rating as a major Results symptom (see Figure 1 ) . Subjects
Of 106 randomized volunteers, 95 (90%) completed all
Biochemical variables study procedures. Forty-six of these received mefloquine and 49 placebo. Age and sex distributions of those on Serum ionised calcium concentrations remained stable over the study period (mean±s.d.; 1.24±0.03 mmol l−1 mefloquine (23.5±6.3 years, 51% males) were not significantly different from those on placebo (24.6±7. 8 at first and final assessment for subjects on active and placebo treatment respectively), as did serum magnesium years, 39% males; P >0.1), and body weights were similar (65.3±11.2 and 66.7±10.6 kg respectively, P= and phosphate (P >0.5). The mean serum albumin fell approximately 1 g l−1 in both groups (P<0.004 baseline 0.26). Eight subjects withdrew after initial assessment and three after the second. Follow-up of these individuals vs final assessment). A progressive fall in serum glucose over the three assessments was observed in those on revealed no toxicity in those allocated mefloquine. Reasons for withdrawal were a lack of time to devote active formulation (5.0±0.7 vs 4.5±0.8 mmol l−1 at baseline and final assessments respectively; P=0.0005). to study procedures, including completion of diaries, in 10 individuals and accidental injury in a volunteer This fall was proportionately greater than that of serum albumin and was accompanied by a significant increase receiving placebo.
in Figure 2 ). No significant changes in serum Compliance and plasma mefloquine concentrations glucose or insulin were seen in the placebo group (P>0.2; see Figure 2 ). Plasma mefloquine concenCompliance appeared full on direct questioning and tablet count at follow-up visits though several volunteers trations at the final assessment and the change in serum insulin over the 5 weeks of the study did not correlate reported taking tablets a day or two late between assessments. Plasma mefloquine and its carboxy metabsignificantly (r=0.203; P=0.09). The lowest serum glucose (2.5 mmol l−1) occurred in asymptomatic indiolite were measurable at both the second and third assessments in all allocated active formulation. After viduals from both groups at the second assessment. two doses, plasma mefloquine ranged from 0.25 to 2.82 (mean 1.52) mmol l−1 and carboxy-metabolite concentrations were from 0.25 to 6.24 (mean 2.35) mmol l−1;
Psychometric testing the average metabolite5drug ratio was 2.0. After the last dose, the equivalent figures were 0.94 to 5.37 (mean Subjects in the two groups had comparable mean baseline scores for all three tests (P>0.14). There was 2.35) mmol l−1 and 1.4 to 9.5 (mean 5.3) mmol l−1 respectively, with an average carboxy-metabolite: a significant improvement in retest gain in SDMT and digit span backwards scores during the study in the mefloquine ratio of 2.6. placebo group (P<0.01). In those allocated mefloquine, significant learning was evident only in the case of SDMT score (P<0.001). However, retest gain at the Symptom reporting third assessment was not significantly different between the two groups for DMST (P=0.25), digit forwards The most common symptom during the run-in week and week after universal placebo was headache.
(P=0.16) and digit backwards (P=0.08) tests (see Figures 3 and 4 ) . Approximately half the total sample experienced at least mild headache (rating ≥1 ) on one or more days during this period (see Table 1 ). This proportion remained relatively constant during the ensuing six Audiometric, blood pressure and electrocardiographic changes weeks. There was no increase in the relative risk of this symptom occurring after the first and last mefloquine dose (see Table 1 ). The number of subjects experiencing There was no significant hearing loss at 6 kHz in either the active or placebo groups over the three assessments major headache (rating ≥5 ) remained low (1 or 2 participants) and comparable between the two groups (P>0.2; see Table 2 ). Supine and erect blood pressure also showed no changes during the study (P >0.2; see throughout. strict procedures for monitoring adverse events were in place, the randomization code did not need to be broken prematurely. Subjects who withdrew were assessed subsequently for evidence of side-effects. As a result, a range of objective data was obtained from a sample of healthy young adults typical of travellers to countries in which malaria transmission occurs. The limitations of the study relate to its environment and duration. Our volunteers remained in familiar home and work surroundings, in contrast to the stimulating world of the traveller. Nevertheless, whether environment accentuates possible mild neuropsychiatric effects of mefloquine is unknown. Although active treatment was given for only 4 weeks, a subject on this regimen is time concentrations of the carboxylic acid metabolite are, on average, more than twice those of mefloquine [23] . Although the final blood sample was not taken at Table 2 ), as did pulse rate (data not shown). There was a statistically significant prolongation in the electrocartrough plasma concentrations in our subjects, metabolite concentrations were usually more than double those of diographic QT c interval between the first and second assessments in the subjects who received mefloquine mefloquine itself. In addition, final peak plasma mefloquine concentrations in more than one in seven of our (P=0.007); a less pronounced and later trend was seen in the placebo group (P=0.03; see Table 2 ). Other subjects were within the range for healthy young travellers (>3.3 mmol l−1) found at the end of 13 weeks electrocardiographic indices (including PR interval and QRS duration) were comparable over the three assessof mefloquine 250 mg weekly [22 ] . At each assessment, subjects were reminded that any ments in both groups of subjects (data not shown).
symptoms should be rated daily. This encouragement might have contributed to the high rate of self-reported headache, lethargy, abdominal pain, diarrhoea, cough and nausea. Nevertheless, mild and transient diarrhoea Discussion was the only symptom significantly associated with mefloquine administration. Nausea and abdominal The present study attempted to minimise bias through several strategies. In addition to a double-blind, placebopain showed a similar tendency, not achieving statistical significance. It is possible that the dosing schedule, controlled design, subjects received an initial placebo before starting regular active medication or identical recommendations regarding pregnancy testing and contraception, and the symptoms listed in the diary placebo. The identity of the active formulation was concealed until the end of the trial. Compliance appeared suggested the identity of the active formulation to volunteers with medical knowledge and/or previous close to complete as assessed from questioning, tablet count and, in those taking mefloquine, by sequential experience of mefloquine through travel. Increased rates and ratings of self-reported neuropsychiatric symptoms, plasma drug and metabolite concentrations. Although and a possible bias against mefloquine, might have been expected in this situation. Given our results and those of other trials involving young volunteers [18 ] , there was little evidence of such an effect in the present study.
In other large-scale studies, nausea, dizziness and headaches were reported by between 6 and 12% of European travellers on mefloquine [ 2] , while strange dreams, insomnia and nausea were present in 10 to 25% of U.S. Peace Corps volunteers on long-term prophylaxis [3 ] . These data suggest that different side- warnings. Nevertheless, gastrointestinal side-effects seem Table 2 Auditory threshold, systolic (SBP) and diastolic (DBP) blood pressure, and QT c interval changes in the two groups. First assessment data are mean±s.d. except for auditory threshold which are median and (interquartile range) for the average of right and left ears. The mean difference from the first assessment and (95% confidence intervals) are listed for the second and third assessments. to be the most consistent in all studies to date. Our both the infrequent reporting of impairment of memory, concentration and motor function by those volunteers data do not support an increase in mild and debilitating neurological symptoms during mefloquine prophylaxis.
on active formulation and previous data from young subjects on long-term mefloquine [3] in whom less than Consistent with known frequency of serious neuropsychiatric reactions from large scale trials [10, 11] , none 2% considered that the drug interfered with daily activities. Median values for 6 kHz auditory threshold was observed in our relatively small sample.
The change in serum albumin over the study period in our subject groups at baseline were similar to that in a recent survey of young adults who were not prein both groups is difficult to explain but of limited biological significance. The stability of serum ionised screened for otological abnormalities (15.5 dB [28 ] ). Despite evidence of high-tone auditory toxicity of calcium and magnesium during weekly mefloquine dosing argues against disturbances in mineral homeoquinine in healthy subjects [29 ], we found no increase in hearing loss due to mefloquine though, due to the stasis contributing to even mild neurological effects. The fall in plasma glucose seen in subjects taking mefloquine testing step used, low-grade (<5 dB) changes may have been missed. Postural blood pressure responses were was proportionately greater than that in serum albumin and appeared to result from relative hyperinsulinaemia.
unaffected by mefloquine. There was, however, transient if mild QT c prolongation which, given that there is Mefloquine is related chemically to the cinchona alkaloids. It is, therefore, possible that it has a quininesome evidence that the interaction between mefloquine and halofantrine may predispose to serious cardiac like effect on the pancreatic beta-cell [24 ] even though the correlation between plasma drug concentrations and arrhythmias [30 ] , suggests that care should be exercised when mefloquine is prescribed with other drugs known changes in serum insulin from baseline did not achieve statistical significance.
to influence ventricular repolarisation. The present study adds to available data confirming There are limited data on the effect of mefloquine on glucose homeostasis. In a study involving seven healthy the relative safety of prophylactic doses of mefloquine in healthy subjects. There was no clear subjective or volunteers, plasma glucose and insulin remained close to baseline during the 6 h after a single dose [25] , a objective evidence of mefloquine-associated neurological dysfunction or cardiovascular toxicity apart from mild period which is much shorter than the time at which maximal plasma mefloquine concentrations are usually and transient QT c prolongation. Gastrointestinal sideeffects were relatively common, especially diarrhoea, but reached [23] . Although our subjects were not studied in a fasting or timed post-prandial state, most attended these symptoms were also mild and short-lived. Significant biochemical changes in subjects on active several hours after eating. Serum glucose and insulin concentrations were largely within post-absorptive formulation were restricted to an average 0.5 mmol l−1 reduction in plasma glucose; under certain circumranges and suggest that peak mefloquine concentrations on a background of regular dosing may result in stances, mefloquine-associated hyperinsulinaemia might have more serious consequences [12, 26, 27] . Although hyperinsulinaemia. This effect, when coupled with other factors such as prolonged fasting or ethanol ingestion, mental stimulation in the form of overseas travel could be an important substrate for subtle mefloquinecould produce hypoglycaemic symptoms and even serious consequences of neuroglycopaenia such as associated neurotoxicity, it is possible that information travellers obtain relating to potential problems of convulsions [12 ] . Recent reports of mefloquineassociated hypoglycaemia in a cachectic patient with antimalarial prophylaxis may also contribute to subsequent symptomatology. AIDS [26] and in an individual after alcohol consumption [27 ] support this hypothesis.
Psychometric testing revealed no significant effects of
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